Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Asset [Yahoo! Finance]
OmniAb, Inc. (OABI)
Company Research
Source: Yahoo! Finance
investigational novel compound with broad potential to treat brain health diseases, excluding the Republic of Korea, China, Hong Kong, Macau and Taiwan Sovargen receives upfront payment and is eligible for future milestone-dependent payments and royalties Agreement further expands Angelini Pharma's strong portfolio and deep therapeutic expertise in brain health, following a series of strategic partnerships in the space, including in orphan and rare epilepsy ROME, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Angelini Pharma, part of the privately owned Angelini Industries, and Sovargen, a South-Korean biotechnology company, announced today that they signed an exclusive global option agreement for the development and commercialization of Sovargen's innovative brain health asset SVG105. Under the terms of the agreement, Angelini Pharma and Sovargen will collaboratively lead the pre-clinical development efforts for SVG105 and, following an initial option period, Angelini Pharma will have th
Show less
Read more
Impact Snapshot
Event Time:
OABI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OABI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OABI alerts
High impacting OmniAb, Inc. news events
Weekly update
A roundup of the hottest topics
OABI
News
- OmniAb to Hold OmniUltra Virtual Investor Event on December 15 [Yahoo! Finance]Yahoo! Finance
- OmniAb to Hold OmniUltra Virtual Investor Event on December 15Business Wire
- OmniAb (NASDAQ:OABI) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors [Yahoo! Finance]Yahoo! Finance
- OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global InvestorsBusiness Wire
OABI
Earnings
- 11/4/25 - In-Line
OABI
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/10/25 - Form 4
- 11/4/25 - Form 10-Q
- OABI's page on the SEC website